Begin main content

upadacitinib

Last Updated: November 8, 2019
Result type: Reports
Project Number: SR0614-000
Product Line: Common Drug Review

Generic Name: upadacitinib

Brand Name: TBC

Manufacturer: AbbVie

Indications: Arthritis, Rheumatoid

Manufacturer Requested Reimbursement Criteria1: Upadacitinib to be listed for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs), as monotherapy or in combination with methotrexate or other conventional synthetic DMARDs (csDMARDs).

Submission Type: New

Project Status: Active

Biosimilar: No

Companion Diagnostics: No

Fee Schedule: Schedule A

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient input postedMay 31, 2019
Patient group input closedJuly 22, 2019
Clarification:

- Patient input submission received from the Arthritis Consumer Experts, Canadian Arthritis Patient Alliance (CAPA) & The Arthritis Society

Patient input summary sent for review to patient input groupsJuly 30, 2019
Patient group comments on input summary closedAugust 07, 2019
Clarification:

- Patient input summary feedback received

Submission receivedJuly 04, 2019
Submission accepted for reviewJuly 18, 2019
Review initiatedJuly 22, 2019
Draft CADTH review report(s) sent to sponsorOctober 04, 2019
Comments from sponsor on draft CADTH review report(s) receivedOctober 16, 2019
CADTH review team's comments on draft CADTH review report(s) sent to sponsorNovember 08, 2019
Canadian Drug Expert Committee (CDEC) meetingNovember 20, 2019
CDEC recommendation sent to sponsor and drug plansDecember 02, 2019
To
December 04, 2019